The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jong Hoo | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Kim, Yee Hyung | - |
dc.date.accessioned | 2021-09-04T13:58:55Z | - |
dc.date.available | 2021-09-04T13:58:55Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-08 | - |
dc.identifier.issn | 0341-2040 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92927 | - |
dc.description.abstract | Background Anti-leukotriene (anti-LT) agents have been not yet established for effectiveness in patients with chronic obstructive pulmonary disease (COPD). We performed a systematic review and meta-analysis to assess whether anti-LT agents have the responsiveness for COPD patients. Methods MEDLINE, EMBASE, Cochrane Central Register, and Korea Med were searched for relevant clinical trials to review. Results Seven studies involving 342 patients were finally analyzed. Pooled estimation from three randomized controlled studies did not demonstrate that anti-LT agents increased forced expiratory volume in 1 s [overall effect: 0.09 L, 95 % confidence interval (CI) -0.04 to 0.21; P = 0.17; I-2 = 41.0 %] or forced vital capacity (overall effect: 0.04 L, 95 % CI -0.04 to 0.11; P = 0.64; I-2 = 0.0 %). As for inflammatory markers, anti-LT agents did not affect the level of myeloperoxidase (standardized mean difference, -0.15; 95 % CI -0.65 to 0.36) or LTB4 (standardized mean difference, -0.41; 95 % CI -0.96 to 0.13). They reduced the frequency of dyspnea [relative risk (RR) 0.43; 95 % CI 0.29 to 0.64] and sputum (RR 0.37; 95 % CI 0.22 to 0.63), based on overall estimation from two non-randomized studies. However, our review revealed that there are few well-designed, randomized controlled studies with large sample sizes and long treatment durations. Conclusion Although symptomatic improvements were demonstrated in some studies, there is a lack of evidence to support the therapeutic efficacy of anti-LT agents in patients with COPD. Further large-scale, long-term studies are needed to identify predictive factors for COPD patients who may benefit from anti-LT agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | EXHALED BREATH CONDENSATE | - |
dc.subject | MONTELUKAST THERAPY | - |
dc.subject | SPUTUM | - |
dc.subject | EXACERBATIONS | - |
dc.subject | ASTHMA | - |
dc.subject | DISEASE | - |
dc.subject | SALMETEROL | - |
dc.subject | TIOTROPIUM | - |
dc.subject | MODERATE | - |
dc.subject | TRIAL | - |
dc.title | The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Jung | - |
dc.identifier.doi | 10.1007/s00408-015-9743-5 | - |
dc.identifier.scopusid | 2-s2.0-84937518828 | - |
dc.identifier.wosid | 000361509300003 | - |
dc.identifier.bibliographicCitation | LUNG, v.193, no.4, pp.477 - 486 | - |
dc.relation.isPartOf | LUNG | - |
dc.citation.title | LUNG | - |
dc.citation.volume | 193 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 477 | - |
dc.citation.endPage | 486 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | EXHALED BREATH CONDENSATE | - |
dc.subject.keywordPlus | MONTELUKAST THERAPY | - |
dc.subject.keywordPlus | SPUTUM | - |
dc.subject.keywordPlus | EXACERBATIONS | - |
dc.subject.keywordPlus | ASTHMA | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | SALMETEROL | - |
dc.subject.keywordPlus | TIOTROPIUM | - |
dc.subject.keywordPlus | MODERATE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Leukotrienes | - |
dc.subject.keywordAuthor | Anti-leukotriene modifiers | - |
dc.subject.keywordAuthor | Chronic obstructive pulmonary disease | - |
dc.subject.keywordAuthor | Treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.